Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Post by boozehound3on Aug 08, 2019 11:57pm

82 Views

Post# 30009483

ISFUK

IF THAT LOUSY CHINESE DEAL IS ALL THEY MUSTER UP THEN YOU ARE RIGHT JUST IMAGINE WHAT WILL HAPPEN TO THE SHARE PRICE

NOTHING HAS CHANGEG HERE FOLKS IMAGINE THE OPTIONS THEY WILL GRANT THEMSELVES FOR THE GREAT JOB THEY ARE DOING

Bullboard Posts

What will the U.S. election results mean for Canada?